EUVIMEDTutustu EUVIMEDiin
Open access · CC BY 4.0

AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence

Soroush Mohammadi Jouabadi iD, Annika A Jüttner, Annique Claringbould, Rene de Vries, Ingrid M Garrelds, Usha Musterd-Bhaggoe, Bruno H Stricker, Maryam Kavousi, A H Jan Danser iD, Fariba Ahmadizar, Anton J M Roks

British Journal of Pharmacology · 2026-09 · 183 (17) · 5389-5406

DOI: 10.1111/bph.70533 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-06-10. Written by Soroush Mohammadi Jouabadi and 10 co-authors. Institution: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Major MEDLINE topics: Metformin, AMP-Activated Protein Kinases, Endothelium, Vascular, Hypoglycemic Agents. Cited 1 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0).

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Background and Purpose Metformin is increasingly recognised for its vasculoprotective effects, primarily through activation of AMP‐activated protein kinase (AMPK). We combined population‐based genetic epidemiology, with an ex vivo vascular model, to investigate the beneficial vascular effects of AMPK activation by metformin. Experimental Approach We used genetically proxied AMPK activation (GP‐AMPK), based on 20 genome‐wide significant single‐nucleotide polymorphisms (SNPs), to assess associations with pulse wave velocity (PWV) and carotid intima‐media thickness (cIMT). A two‐sample Mendelian randomisation (MR) was performed to test the effect of GP‐AMPK on a panel of inflammatory markers. We also developed a porcine coronary artery model of endothelial dysfunction to test the restorative effects of metformin on vascular function and related molecular signalling pathways. Key Results Higher GP‐AMPK activation was associated with lower PWV, but not cIMT, in our epidemiological analysis (mean age 64.3 years, 43.8% female). Ex vivo, metformin restored endothelial relaxation in Angiotensin (Ang) II–treated vessels via endothelium‐dependent hyperpolarisation (EDH) mechanisms, an effect abolished by AMPK inhibition. Western blotting confirmed the activation of AMPK (alpha 1 subunit) with metformin treatment. Inhibitor studies demonstrated a shift from NO‐mediated to EDH‐mediated relaxation with metformin. Molecular analyses showed reduced Ang II–induced expression of matrix remodelling (MMP1, MMP2) and senescence (P21) markers, as well as suppression of pro‐inflammatory cytokines (Il‐1β, Il‐6, TNF‐α), consistent with MR results. Conclusion and Implications Metformin restored endothelial function and reduced vascular stiffness through an AMPK–EDH axis, highlighting a novel, potential therapeutic mechanism for early vascular dysfunction independent of glycaemic effects.

Subjects

MeSH terms (MEDLINE)

MetforminAMP-Activated Protein KinasesEndothelium, VascularHypoglycemic AgentsAnimalsFemaleHumansMaleSwineCarotid Intima-Media ThicknessPolymorphism, Single NucleotidePulse Wave Analysis

Author keywords

AMPKEDH pathwayendothelial dysfunctionmetformin

Substances

MetforminAMP-Activated Protein KinasesHypoglycemic Agents

Authors and institutions

  • Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Data Science and Biostatistics, Julius Global Health, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

ORCID profiles: Soroush Mohammadi Jouabadi, A H Jan Danser

Cite

APA

Mohammadi Jouabadi, S., Jüttner, A. A., Claringbould, A., de Vries, R., Garrelds, I. M., Musterd-Bhaggoe, U., Stricker, B. H., Kavousi, M., Danser, A. H. J., Ahmadizar, F., & Roks, A. J. M. (2026). AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence. British Journal of Pharmacology, 183(17), 5389-5406. https://doi.org/10.1111/bph.70533

Vancouver

Mohammadi Jouabadi S, Jüttner AA, Claringbould A, de Vries R, Garrelds IM, Musterd-Bhaggoe U, et al. AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence. British Journal of Pharmacology. 2026;183(17):5389-5406. doi:10.1111/bph.70533

BibTeX
@article{MohammadiJouabadi2026,
  author = {Mohammadi Jouabadi, Soroush and Jüttner, Annika A and Claringbould, Annique and de Vries, Rene and Garrelds, Ingrid M and Musterd-Bhaggoe, Usha and Stricker, Bruno H and Kavousi, Maryam and Danser, A H Jan and Ahmadizar, Fariba and Roks, Anton J M},
  title = {AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {17},
  pages = {5389--5406},
  doi = {10.1111/bph.70533}
}
Start for free →